Front Page News
Cure SMA Posts Keynote Presentations on the NDA Process
The ultimate goal in drug development is to get treatments approved for as many people as possible, as quickly as possible. Because these issues are […]
Read More ›Cure SMA Funds $2 Million in New Research in 2015-2016
Over the past few months, Cure SMA has announced a total of just over $2 million in new research funding. Our model is designed to […]
Read More ›The 2016 Annual SMA Conference is Here!
The 2016 Annual SMA Conference, now in its 28th year, is set to kick off on June 16 and continue into a weekend full of […]
Read More ›Cure SMA Awards $304,000 Drug Discovery Grant to Livio Pellizzoni, PhD, at Columbia University
Cure SMA has awarded a $304,000 drug discovery grant to Livio Pellizzoni, PhD, at Columbia University. The award is for the project, “Pharmacological Inhibition of […]
Read More ›Cure SMA Receives 2016 NIH Grant
For the eighth consecutive year, Cure SMA has received a grant from the National Institutes of Health (NIH) for the SMA Researcher Meeting. This year’s […]
Read More ›Cure SMA Announces Biogen as Presenting Sponsor for the 2016 Annual SMA Conference
Cure SMA is pleased to announce that Biogen will be the Presenting Sponsor for our 2016 Annual SMA Conference. This year’s conference is set to […]
Read More ›Cure SMA Releases June 2016 Update to the SMA Drug Pipeline
We’ve recently released an update to the SMA drug pipeline. This latest version includes: 18 active programs. 14 pharmaceutical partners. 6 programs in clinical trials. […]
Read More ›Thank you to Our 2016 Annual SMA Conference Exhibitors!
Thank you to the following exhibitors who have generously supported our 2016 Annual SMA Conference. This one-of-a-kind event would not be possible without your support! […]
Read More ›Biogen and Ionis Release Spring 2016 Community Update
Biogen and Ionis Pharmaceuticals recently provided an update on the clinical development of nusinersen (IONIS-SMNRx), which is currently being tested in Phase 3 clinical trials: […]
Read More ›2016 Update on SMA-FDA Interactions
The SMA drug pipeline has grown dramatically in just over a decade. Of the 18 programs in the pipeline, six of these are in clinical […]
Read More ›